My phenotype speaks: please do not harm me with biopsy needle

Saini I¹, Bagri N¹, Gupta N¹

ACTA REUMATOL PORT. 2018;43:156-158

INTRODUCTION

Fibrodysplasia ossificans progressiva (FOP) is a disabling genetic disorder of connective tissue characterized by congenital malformation of the great toes and progressive heterotopic ossification of muscle and connective tissue¹. It is extremely rare and has a prevalence of one in two million people¹. Children are normal at birth except for a malformation of the great toes². The progressive heterotopic ossification usually begins in the first decade of life, and occurs in a specific anatomic pattern³. FOP has a relapsing and remitting nature and is often precipitated by trauma, intramuscular injections, muscle fatigue, viral infections, or diagnostic biopsies and invasive surgical procedures, and results in debilitating pain and permanent disability^{1,4}.

CASE

A 4-year-old boy presented with multiple hard lumps over his neck and back, and which had gradually developed and progressively worsened over the past 2 years. There was no family history of similar illness and there was no significant history of trauma. Physical examination revealed multiple, non-tender, mobile bony hard subcutaneous swellings in the neck, and back (Figure 1A). He also had significant neck stiffness, and the great toes were short with valgus deformity (Figure 2). Radiographs revealed ossification of the ligamentum nuchae and heterotopic ossification (HO) over the neck anteriorly in midline, left lower hemithorax, abdomen and thoracic and lumbar spine, consistent with the site of the lesions on neck and back (Figures 1B,3,4,). Biochemical evaluations of bone mineral metabolism were normal. These characteristic lesions suggested the diagnosis of fibrodysplasia ossificans pro-

1. Pediatrics, All India Institute of Medical Sciences, New Delhi, India

gressiva (FOP). Bidirectional sanger sequencing showed presence of the common heterozygous activating mutation (c.617G>A; R206H) in the ACVR1, a bone morphogenetic protein (BMP) type I receptor. The



FIGURE 1. A) Bony hard masses over back; **B**) Chest and abdominal radiograph showing heterotopic ossification over left lower hemithorax and abdomen



FIGURE 2. Feet showing hallux valgus deformities



FIGURE 3. Neck radiograph showing the ossification of ligamentum nuchae and heterotopic ossification anteriorly

child had undergone non yielding biopsies from multiple sites before the final diagnosis was made.

DISCUSSION

Despite the distinct constellation of defining clinical features, FOP is often misdiagnosed and 67% undergo unnecessary harmful diagnostic procedures like biopsies as in our case which leads to posttraumatic ossification and permanent loss of mobility in more than 50%⁴.

The mutation causing the disease is highly specific and localized to the activin receptor A type I/activinlike kinase 2 (ACVR1/ALK2) gene, which encodes a bone morphogenic protein (BMP)². Nearly all cases arise by spontaneous mutations, but autosomal dominant inheritance has been observed². There is no definite and effective treatment for FOP⁵.

The best treatment is still prevention of trauma, with possible role of glucocorticoids in the acute flare-ups. The most effective way to prevent the acute flare-ups is by early diagnosis of the condition and by subsequent avoidance of trauma and iatrogenic harm¹. Mal-



FIGURE 4. Radiograph showing heterotopic ossification over abdomen and thoracic and lumbar spine

formations of the great toes are universal and present in all affected individuals¹. Although all children with malformed great toes will not have FOP, it must be part of the differential diagnosis. Once the soft tissue swellings appear, the clinical diagnosis is certain¹. Hence, clinicians need to be vigilant in any child presenting with soft tissue swellings and having malformed great toes, so that the early diagnosis may be made and iatrogenic harm avoided.

CORRESPONDENCE TO Narendra Bagri Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110049 E-mail: drnarendrabagri@yahoo.co.in

REFERENCES

- 1. Kaplan FS, Xu M, Glaser DL, et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 2008;121: e1295-300.
- Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006;38: 525--527.
- Kaplan FS, Glaser DL, Shore EM, et al. The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Mineral Metabol 2005;3: 183-188.
- 4. Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005;116: e654-661.
- Kaplan FS, Shore EM, Pignolo RJ. The international clinical consortium on FOP. The medical management of fibrodysplasia ossificans progressive: current treatment considerations. Clin Proc Intl Consort FOP 2011;4: 1-100.